Struggling Fibrocell To Consider All Strategic Directions Going Forward

 
• By Joseph Haas

Focused on autologous fibroblast cell therapies for rare diseases, the biotech appears cash-poor despite one candidate moving into Phase II and another ready to enter the clinic.

A pair of feet standing on a tarmac road with yellow arrow print pointing in three different directions for the concept of making decision at the crossroad.

More from Strategy

More from Business